EBEnrique Alexander Berrios Barcenas

Enrique Alexander Berrios Barcenas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Enrique Alexander Berrios Barcenas has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Screening of fabry disease in patients with left ventricular hypertrophy: a single-center study in Mexico

    by Dante Palacios Gutierrez, Gabriela Meléndez-Ramirez, Edith Liliana Posada Martínez, Blanca Rebeca Ibarra-Ibarra, Solange Gabriela Koretzky, Maria Cecilia Escalante Seyffert, Francisco Javier Roldán Gómez, Aloha Meave Gonzalez Ramirez, Lucía de Montserrat Sabido González, Daniel Vera Ibarra, et al.

    Background: Fabry disease (FD) is an X-linked sphingolipidosis caused by enzyme α-Galactosidase A (α-Gal A) deficiency due to pathogenic variants in GLA gene. Progressive glycosphingolipid accumulation leads to subsequent myocyte injury, which frequently induces concentric remodeling and manifests as left ventricular hypertrophy (LVH). This study aims to describe the prevalence of FD in patients with LVH diagnosis in a Mexican population. Methods: Consecutive and unrelated patients with echocardiographic evidence of left ventricular hypertrophy (LVH) without known cause were screened for FD in a Mexican cardiology referral center. Globotriaosylsphingosine (lyso-Gb3) levels and α-Gal A activity were measured using the dry blood spot method in all male individuals. Patients with positive dried blood spot testing and female patients were confirmed by single-gene sequencing. Results: 205 patients with LVH (48.5 ± 18.7 years) were included. Of these, 53% were male, 60% were in NYHA functional class I, and 43% were asymptomatic. Dyspnea was the most frequently reported symptom, occurring in 26% of cases. Among study participants, three women were diagnosed with FD (1.5%). GLA gene sequencing revealed two pathogenic variants, NM_000169.3( GLA ):c.559 A > G (p.Met187Val) and NM_000169.3( GLA ):c.679 C > T (p.Arg227Ter), and a variant of unknown significance (VUS) reclassificated to a likely pathogenic variant NM_000169.3( GLA ):c.122 C > G (p.Thr41Ser). Cascade screening identified three additional women with FD. Conclusion: These results emphasize the need for genetic screening for FD in female individuals with LVH. Further studies are needed to understand genotype-phenotype correlations in females with genetic variants in the GLA gene, particularly those with VUS and novel variants, as they pose challenges for diagnosis and treatment.

  • Open Access

    Gut–Heart Axis: Microbiome Involvement in Wild-Type Transthyretin Amyloidosis

    by Itzel Ivonn López-Tenorio, Luis Alejandro Constantino-Jonapa, Samuel Jaimez-Alvarado, Fernando Hernández-Quiroz, Esteban Jorge-Galarza, Alma Reyna Escalona-Montaño, Amedeo Amedei, Rodrigo Soria-García, Enrique Alexander Berrios-Barcenas, María Magdalena Aguirre-García

    Cardiac amyloidosis is a rare and progressive condition characterized by the extracellular deposition of amyloid fibrils in multiple organs. Wild-type transthyretin amyloidosis (ATTR-wt) is the most common type affecting subjects above 60 years old. Recent and growing evidence suggests a potential link between GM and cardiac amyloidosis. In this scenario, the aim of the present study is to characterize the gut microbiota (GM), related metabolites and inflammatory biomarkers in ATTR-wt patients. In the ATTR patients we identified Prevotella_9 as the core OTUs (Operational Taxonomic Unit) of this group, alongside Prevotella 7, Prevotellaceae_UCG-003 and Prevotellaceae_NK3B31. In addition, there were increased levels of long fatty acids, including tetradecanoic, hexadecanoic and octadecanoic acids, in the ATTR group. The data obtained suggest that ATTR patients have an altered gut microbiota that could be used as a potential biomarker in metabolic and cardiovascular diseases, as well as a potential predictor of adverse prognosis in ATTR patients. In addition, the intestinal dysbiosis in ATTR patients could be associated with low-grade endotoxemia promoting a pro-inflammatory state due to the translocation of bacterial components, such as LPS (lipopolysaccharide), into blood circulation.